GLP-1 receptor agonists may help women with obesity reach fertility treatment eligibility faster by enabling rapid weight loss and improving metabolic health, but safety data for preconception use are still limited.
BMI ≥30Common clinic threshold that bars women from fertility treatment — GLP-1 drugs may help them reach eligibility faster
What the researchers found
This review examines whether GLP-1 receptor agonists could help women with obesity improve their fertility by enabling rapid preconception weight loss. Women with elevated BMI take longer to conceive and have poorer outcomes from fertility treatments, and many clinics require a BMI under 30 before starting IVF. GLP-1 drugs offer faster weight loss than diet and exercise alone, and may also reverse some of the metabolic dysfunction associated with obesity and polycystic ovarian syndrome (PCOS) — both of which impair fertility.
The review finds this is an emerging but promising area: GLP-1 agonists could help women reach treatment-eligible weight faster, which matters because reproductive potential declines with age. However, the authors note significant gaps in safety data regarding preconception use and highlight ethical considerations around prescribing these drugs specifically for fertility access.
Why it matters
Many women with obesity face a double bind: they need to lose weight to access fertility treatment, but the time spent losing weight reduces their remaining fertile years. If GLP-1 drugs can safely accelerate preconception weight loss while also improving the metabolic conditions (like insulin resistance in PCOS) that impair fertility, they could transform reproductive care for overweight women.
The numbers in context
BMI ≥30 threshold commonly required by fertility clinics · Obesity associated with longer time to conception · PCOS affects metabolic and reproductive function
How the study worked
Narrative review summarizing existing literature on obesity's effects on female fertility, the pharmacology of GLP-1 receptor agonists, and emerging evidence for their use in improving fertility outcomes in women with obesity and PCOS.
Who was studied
Women with obesity (BMI ≥30) seeking fertility treatment, including those with PCOS
What this study cannot tell us
This is a narrative review, not a systematic review or meta-analysis. It synthesizes existing knowledge rather than presenting new data. The evidence for GLP-1 agonists specifically improving fertility outcomes is still limited and emerging. Safety data for preconception GLP-1 use are lacking, and the required washout period before conception adds complexity.
How to read the evidence
This is a narrative review summarizing existing literature. While it provides a comprehensive overview, it does not present new data or use systematic methodology, so the evidence level reflects the quality of the underlying studies reviewed.
When this study was published
Published in 2026. This is a very current review addressing an active and rapidly evolving area of research as GLP-1 drug use expands among women of reproductive age.
The bigger picture
This sits at the intersection of two major trends: the explosion of GLP-1 drug use for weight management and growing recognition that obesity is a significant barrier to reproductive success. As GLP-1 prescriptions surge, more women of reproductive age are using these drugs, making the question of preconception safety and fertility benefits increasingly urgent for both patients and clinicians.
Questions still open
- How long before conception must GLP-1 drugs be stopped to ensure fetal safety?
- Do the metabolic improvements from GLP-1 treatment (insulin sensitivity, hormonal balance) persist long enough after drug cessation to benefit conception and early pregnancy?
- Could GLP-1 agonists improve IVF success rates beyond what weight loss alone would achieve?
Common questions
Can you take GLP-1 drugs like Ozempic while trying to get pregnant?
Why does obesity make it harder to get pregnant?
Read the original research
Obesity and Female Reproductive Health; Is There a Role for Glucagon-Like Peptide-1 Receptor Agonists?
Obesity reviews : an official journal of the International Association for the Study of Obesity, 27(2), e70015
Citation
Roberts, Rachel; Markande, Anurag; Kasaven, Lorraine; Williams, Sarah Chieveley; Faris, Raef; Bracewell-Milnes, Timothy; Thum, Yau; Nicopoullos, James; Jones, Benjamin P. (2026). Obesity and Female Reproductive Health; Is There a Role for Glucagon-Like Peptide-1 Receptor Agonists?. Obesity reviews : an official journal of the International Association for the Study of Obesity, 27(2), e70015. https://doi.org/10.1111/obr.70015